Eton Pharmaceuticals

Yahoo Finance • 6 days ago

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 18 days ago

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 22 days ago

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATE Thursday, November 6, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Sean BrynjelsenChief Financial Officer — James GruberExecutive Vice President, Corporate Development — David Kre... Full story

Yahoo Finance • 24 days ago

Eton outlines fivefold INCRELEX market opportunity and targets $50M peak adrenal franchise sales amid record Q3 growth

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q3 2025 MANAGEMENT VIEW * Sean Brynjelsen, President, CEO & Director, announced "another record quarter for the company with triple-digit year-over-year revenue growth" and highlighte... Full story

Yahoo Finance • last month

3 Growth Companies With Insider Ownership Up To 31%

As major stock indexes in the United States continue to reach new heights, driven by significant developments such as Nvidia's landmark $5 trillion market cap and anticipation around Federal Reserve decisions, investors are keenly watching... Full story

Yahoo Finance • 3 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 4 months ago

Eton targets $80M revenue run-rate in Q3 2025 as product launches accelerate

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2025 MANAGEMENT VIEW * CEO Sean E. Brynjelsen stated that "it was another record quarter for the company" and described 2025 as "the most exciting time in our history." He highligh... Full story

Yahoo Finance • 4 months ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 5 months ago

Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer

Company Logo The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticos... Full story

Yahoo Finance • 5 months ago

FDA accepts Eton's NDA for ET-600 desmopressin oral solution

DEER PARK, Ill. - Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company with a market capitalization of $386 million and an impressive 323% return over the past year, announced Tuesday that the U.S. Food and Drug Adm... Full story

Yahoo Finance • 5 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovat... Full story

Yahoo Finance • 5 months ago

Eton Pharmaceuticals to join Russell indexes

* Eton Pharmaceuticals (NASDAQ:ETON [https://seekingalpha.com/symbol/ETON]) will be added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes, as part of the 2025 Russell Indexes reconstitution. * The addition is effect... Full story

Yahoo Finance • 5 months ago

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 6 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution • Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50... Full story

Yahoo Finance • 7 months ago

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully... Full story

Yahoo Finance • 8 months ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today an... Full story

Yahoo Finance • 8 months ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClo... Full story

Yahoo Finance • 9 months ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmace... Full story

Yahoo Finance • 9 months ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today a... Full story

Yahoo Finance • 9 months ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients – – $0 co-pay for all eligible patients and best-in-class patient support services – – Now available exclusively through Optime... Full story